Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,647 stopped studies mapped to Malignant Lung Neoplasm and descendants · 90% state a reason
Over the 1,647 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01511081 | Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) | Phase 2 | terminated | Jan 18, 2012 | M.D. Anderson Cancer Center | Low Accrual | Enrollment / accrual |
| NCT03130764 | Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC | Phase 2 | withdrawn | Apr 26, 2017 | Columbia University | PI Transferred | Other (stated, no rule matched) |
| NCT01342770 | Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung… | Phase 2 | terminated | Apr 27, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01228435 | IPI-504 in NSCLC Patients With ALK Translocations | Phase 2 | terminated | Oct 26, 2010 | Massachusetts General Hospital | slow accrual | Enrollment / accrual |
| NCT02947113 | Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC(HYPOLAN) | Phase 2 | withdrawn | Oct 27, 2016 | The Netherlands Cancer Institute | New studies available with immunotherapy so recruitment is no longer acceptable. | Enrollment / accrual |
| NCT00356941 | Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable… | Phase 1 | terminated | Jul 27, 2006 | Masonic Cancer Center, University of Minnesota | Withdrawn due to lack of accrual | Enrollment / accrual |
| NCT00619021 | Bronchial Artery Infusion of Gemcitabine in Treating Patients With Recurrent or… | Phase 1 | terminated | Feb 20, 2008 | Masonic Cancer Center, University of Minnesota | Funding and study drugs unavailable | Funding |
| NCT00526890 | Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients… | Phase 2 | terminated | Sep 10, 2007 | Roswell Park Cancer Institute | lack of efficacy | Efficacy / futility |
| NCT01746810 | IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large… | Phase 1 | terminated | Dec 11, 2012 | New Mexico Cancer Research Alliance | Closed study as requested by PI due to lack of accruals | Enrollment / accrual |
| NCT02297087 | Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for… | N/A | terminated | Nov 21, 2014 | Western Regional Medical Center | PI no longer at site and he does | Other (stated, no rule matched) |
| NCT02405910 | Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC. | Phase 2 | withdrawn | Apr 1, 2015 | West Virginia University | PI Left Institution | Investigator |
| NCT00932152 | Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With… | Phase 2 | terminated | Jul 3, 2009 | University of Pittsburgh | Poor enrollment/suspended to accrual; will close per AstraZeneca request | Enrollment / accrual |
| NCT00534209 | Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have… | Phase 1 / Phase 2 | terminated | Sep 24, 2007 | University of Miami | Per request of Principal Investigator this study was closed. | Investigator |
| NCT00003491 | Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT00003495 | Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow accrual | Enrollment / accrual |
| NCT00003496 | Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell… | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | slow accrual | Enrollment / accrual |
| NCT01065818 | Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET | N/A | terminated | Feb 9, 2010 | Columbia University | Lack of funding | Funding |
| NCT00188526 | Computed Tomography (CT) Guided Lung Biopsy: Core or Fine Needle Aspiration | N/A | withdrawn | Sep 16, 2005 | University Health Network, Toronto | Unknown Reason | Other (stated, no rule matched) |
| NCT02695290 | Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status… | Phase 4 | terminated | Mar 1, 2016 | Boehringer Ingelheim | not stated | Not stated |
| NCT01799395 | Prevalence and Incidence of Central Airway Obstruction in Advanced Lung Cancer | — | terminated | Feb 26, 2013 | Maggiore Bellaria Hospital, Bologna | Staff constraints made it impossibile to enroll consecutive patients, making the sample not… | Enrollment / accrual |
| NCT00881712 | Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)(LU02) | N/A | terminated | Apr 15, 2009 | University of Florida | projected enrollment rate not feasible | Enrollment / accrual |
| NCT02876081 | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV…(THEN) | Phase 2 | withdrawn | Aug 23, 2016 | Fondation Hôpital Saint-Joseph | medical decision | Other (stated, no rule matched) |
| NCT02121899 | Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage…(ONC006) | — | terminated | Apr 24, 2014 | Myriad Genetic Laboratories, Inc. | company decision to terminate | Sponsor / business decision |
| NCT02121925 | Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in…(ONC003) | — | terminated | Apr 24, 2014 | Myriad Genetic Laboratories, Inc. | Company decision to terminate | Sponsor / business decision |
| NCT02538627 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | Phase 1 | terminated | Sep 2, 2015 | Merrimack Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT02924233 | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified… | Phase 1 / Phase 2 | withdrawn | Oct 5, 2016 | Symphogen A/S | Symphogen made a business decision to no longer perform the clinical study | Sponsor / business decision |
| NCT02950792 | MRI Adaptive Replanning Using ViewRay | N/A | withdrawn | Nov 1, 2016 | University of Miami | Investigator Decision | Investigator |
| NCT02049151 | Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer(START2) | Phase 3 | terminated | Jan 30, 2014 | EMD Serono | The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide… | Sponsor / business decision |
| NCT01398124 | Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell… | N/A | withdrawn | Jul 20, 2011 | Milton S. Hershey Medical Center | We will not be pursuing this study. | Other (stated, no rule matched) |
| NCT02835599 | Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now(REVOLUTION) | — | terminated | Jul 18, 2016 | AstraZeneca | The study sponsor requested the study be terminated as the existing study design did not meet their… | Other (stated, no rule matched) |
| NCT02715102 | Circulating Tumor DNA in Patients at High Risk for Lung Cancer | — | terminated | Mar 22, 2016 | Pathway Genomics | Patient accrual was slow due to exclusion of patients with prior cancers | Enrollment / accrual |
| NCT02425072 | NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer | Phase 2 | withdrawn | Apr 23, 2015 | John Villano | slow accrual | Enrollment / accrual |
| NCT02639234 | Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer | Phase 2 | withdrawn | Dec 24, 2015 | Gradalis, Inc. | not stated | Not stated |
| NCT00791336 | Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer | Phase 2 | terminated | Nov 14, 2008 | University of Iowa | Poor enrollment. | Enrollment / accrual |
| NCT01575782 | Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung…(Chloroquine) | Phase 1 | terminated | Apr 11, 2012 | Maastricht Radiation Oncology | Poor accrual | Enrollment / accrual |
| NCT00454324 | Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer(NRR) | Phase 2 | terminated | Mar 30, 2007 | UNC Lineberger Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT03042013 | A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study | Phase 2 | withdrawn | Feb 3, 2017 | Astellas Pharma Global Development, Inc. | Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies. | Enrollment / accrual |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of… | Phase 1 / Phase 2 | withdrawn | Aug 6, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01936961 | Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid…(I-CREST) | N/A | withdrawn | Sep 6, 2013 | Western Regional Medical Center | No patients enrolled | Enrollment / accrual |
| NCT00280748 | Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases…(NRR) | Phase 2 | terminated | Jan 23, 2006 | UNC Lineberger Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT00958022 | Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer | Phase 1 | terminated | Aug 13, 2009 | Ahmad Tarhini | Based on the tolerabilty challenges of the combination | Other (stated, no rule matched) |
| NCT02495636 | Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent… | Phase 2 | withdrawn | Jul 13, 2015 | Yale University | Study closed due to lack of enrollment | Enrollment / accrual |
| NCT00662311 | Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate… | Phase 1 / Phase 2 | terminated | Apr 21, 2008 | University of Washington | not stated | Not stated |
| NCT00519831 | Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC | Phase 2 | terminated | Aug 23, 2007 | UNC Lineberger Comprehensive Cancer Center | Drug unavailable | Other (stated, no rule matched) |
| NCT00266812 | Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients… | Phase 2 | terminated | Dec 19, 2005 | Merck Sharp & Dohme LLC | Patient target could not be reached within the planned timeframe. | Other (stated, no rule matched) |
| NCT00423150 | Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study… | Phase 2 | terminated | Jan 18, 2007 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00632203 | Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV… | Phase 2 | terminated | Mar 10, 2008 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00592007 | Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell… | Phase 2 | terminated | Jan 11, 2008 | Lyudmila Bazhenova, M.D. | Study was terminated due to slow subject accrual | Enrollment / accrual |
| NCT02570958 | ENB Robotic ICG Guided Surgery: A Novel Technique for Targeting Small Lung Tumors(ENB-RIGGS) | Phase 1 | withdrawn | Oct 7, 2015 | St. Joseph's Healthcare Hamilton | Funding was not received | Funding |
| NCT01336894 | Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body… | Phase 3 | terminated | Apr 18, 2011 | Alliance for Clinical Trials in Oncology | recruiting or enrolling participants has halted prematurely and will not resume; participants are… | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 7, 2017source: clinicaltrials